185 related articles for article (PubMed ID: 8485018)
1. Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Weller C; O'Neill CJ; Charlett A; Bowes SG; Purkiss A; Nicholson PW; Dobbs RJ; Dobbs SM
Br J Clin Pharmacol; 1993 Apr; 35(4):379-85. PubMed ID: 8485018
[TBL] [Abstract][Full Text] [Related]
2. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
Bowes SG; Dobbs RJ; Henley M; Charlett A; O'Neill CJ; Nicholson PW; Purkiss AG; Weller C; Dobbs SM
Eur J Clin Pharmacol; 1992; 43(5):483-9. PubMed ID: 1483485
[TBL] [Abstract][Full Text] [Related]
3. Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.
Bowes SG; Clark PK; Leeman AL; O'Neill CJ; Weller C; Nicholson PW; Deshmukh AA; Dobbs SM; Dobbs RJ
Br J Clin Pharmacol; 1990 Jul; 30(1):13-24. PubMed ID: 2202385
[TBL] [Abstract][Full Text] [Related]
4. Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.
Bowes SG; Clark PK; Charlett A; O'Neill CJ; Leeman AL; Weller C; Nicholson PW; Deshmukh AA; Dobbs SM; Dobbs RJ
Br J Clin Pharmacol; 1991 Mar; 31(3):295-304. PubMed ID: 2054270
[TBL] [Abstract][Full Text] [Related]
5. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
[TBL] [Abstract][Full Text] [Related]
6. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne UK; Rinne JO
Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
[TBL] [Abstract][Full Text] [Related]
9. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Greenacre JK; Coxon A; Petrie A; Reid JL
Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
11. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
12. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
Cedarbaum JM; Silvestri M; Clark M; Toy L; Harts A; Green-Parsons A; McDowell FH
J Neural Transm Park Dis Dement Sect; 1990; 2(3):205-13. PubMed ID: 2257060
[TBL] [Abstract][Full Text] [Related]
13. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Hutton JT; Morris JL
Can J Neurol Sci; 1991 Nov; 18(4):467-71. PubMed ID: 1782612
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of equivalent efficacy of sinemet and sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula.
Manyam BV; Hare TA; Robbs R; Cubberley VB
Clin Neuropharmacol; 1999; 22(1):33-9. PubMed ID: 10047932
[TBL] [Abstract][Full Text] [Related]
16. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
Bulling MT; Wing LM; Burns RJ
Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
[TBL] [Abstract][Full Text] [Related]
18. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Steiger MJ; Stocchi F; Bramante L; Ruggieri S; Quinn NP
Clin Neuropharmacol; 1992 Dec; 15(6):501-4. PubMed ID: 1477849
[TBL] [Abstract][Full Text] [Related]
19. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
LeWitt PA
Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
